Navigation Links
Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
Date:4/3/2012

WORCESTER, Mass. and TORONTO, April 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the American Association for Cancer Research (AACR) chose to spotlight a presentation on data from the ongoing clinical trial of AE37, an immunotherapeutic vaccine to prevent relapse in patients who have had breast cancer being developed by Antigen Express, in a press conference.  The annual AACR meeting is one of the largest national cancer conferences in the US, highlighting the most significant advances in all areas of cancer research.  It is being held this year from March 31 to April 4 at McCormick Place in Chicago, Il.

The specific presentation highlighted by the AACR is entitled: "Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine" by Dr. Diane Hale et al.  The abstract will be available for viewing Tuesday April 3rd from 8 AM to 12 PM.  The study examined patients from the controlled, randomized trial of AE37 for immunological response to the vaccine.  AE37 consists of a fragment of the HER2 protein modified by proprietary means to increase potency in generating a specific immune response to HER2 expressing cancer cells.  The key findings from the study are that patients receiving AE37 indeed developed a specific immune response as indicated by an increase in circulating T cells in their blood specific for the HER2 fragment as well as a positive skin test (delayed type hypersensitivity).  In addition, patients receiving AE37 demonstrated a reduction in T regulatory cells, which are know to be able to hamper an immune response.

The AACR press conference was held Monday April 2nd.  Dr. Hale gave a brief oral presentation of the study followed by a question and answer period.

"The finding that AE37 generates a specific immune response is consistent with the activity we've observed to date, suggesting that patients receivi
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
2. Generex Secures Commitments for $3.6M Capital Raise
3. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
4. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
7. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
8. Generex Provides Update on Spinout of Antigen Express
9. Generex Augments Cash Position With Sales of Non-Essential Assets
10. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
11. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Charlotte, NC (PRWEB) October 24, 2014 ... high intensity focused ultrasound (HIFU) technology, announced that ... Carol, M.D. as Chief Executive Officer, President and ... new role Dr. Carol will take-on expanded responsibilities ... HIFU technology, as well as overseeing commercialization, manufacturing ...
(Date:10/25/2014)... JERUSALEM , October 24, 2014 ... a clinical-stage pharmaceutical company focused on the development of ... CEO, Nadav Kidron will present at FireRock ... ,FireRock Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, ... Building, New York City , ...
(Date:10/25/2014)... 2014 Investor-Edge has initiated coverage ... CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ... Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended on a positive note as the Dow Jones ...
(Date:10/22/2014)... 22, 2014 New test innovations will be ... diagnostic (IVD) test industry, especially as companies struggle with ... listed more than 25 testing innovations in important disease ... of IVD products. Kalorama details the new approaches its biennial ... for In Vitro Diagnostic Tests , 9th Edition ...
Breaking Biology Technology:SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3
... Inc. (Nasdaq:,BIOD) today reported financial results for its second quarter ... $9.6 million or $0.43 per share., "We remain on ... and Chairman of Biodel. "The last patient visits for,both pivotal ... We,expect to announce top line data late in the third ...
... Pennsylvania and OXFORD, England, May 9 ,EUSA Pharma ... oncology, pain control and critical care, today announced ... following the,approval of Cytogen,s shareholders at a special ... of the acquisition agreement, Cytogen shareholders will,receive $0.62 ...
... Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that the ... 2008 Healthcare Conference on May 14, 2008 at 5:20 ... Seasons Hotel in Las,Vegas, Nevada. Dominic P. Behan, Ph.D., ... to provide an overview of the,company, including its clinical ...
Cached Biology Technology:Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 2Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 3Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 4Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 5Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 6Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 7Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 8Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 9EUSA Pharma Completes Acquisition Of Cytogen Corporation 2EUSA Pharma Completes Acquisition Of Cytogen Corporation 3Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 2Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 3
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
(Date:10/16/2014)... Syncytial Virus causes severe respiratory tract infections and ... year. Scientists at VIB and Ghent University have ... counteract this common virus infection. , Xavier ... that paves the way for the development of ... virus that causes suffering in numerous small children ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... In recent years, the possible applications for double-walled ... those working on developing renewable energy technologies. These ... thin enough to be transparent, yet can still ... advanced solar panels, sensors and a host of ...
... for Glycomics in collaboration with colleagues at the ... to identifying a broad spectrum treatment for the ... These highly-infectious viruses are the leading cause of ... of hospitalisations in the developed world, and hundreds ...
... Dec. 23, 2008 -- The reproductive spores of many ... to new research by mycologists and applied mathematicians at ... this week in the Proceedings of the National ... fungal spores is within one percent of the absolute ...
Cached Biology News:Researchers find chink in the armor of viral 'tummy bug' 2In many fungi, reproductive spores are remarkably aerodynamic 2
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
... T4 DNA Ligase catalyzes the joining of ... and the 3´-hydroxyl groups of adjacent nucleotides ... (1). The enzyme has also been shown ... either a DNA or RNA strand in ...
... Chain MAP1A and MAP1B are microtubule-associated proteins ... components of the cytoskeleton. MAP1A and MAP1B each ... light chain subunits. The protein encoded by this ... and can associate with either MAP1A or MAP1B. ...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Biology Products: